Key facts
- This page summarizes Abhinav Jain's Form 4 filing for AYTU BIOPHARMA, INC (AYTU).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jul 2026, 16:31.
Abhinav Jain - 28 Jul 2026 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)
- Reporting relationship
- Director
- Issuer ticker
- AYTU
- Reported as of
- 28 Jul 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jul 2026, 16:31:51 UTC
- Prior SEC filing
- 24 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan J. Selhorn as attorney-in-fact for Abhinav Jain
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Abhinav Jain filed Form 4 for AYTU BIOPHARMA, INC (AYTU) on 30 Jul 2026.
Change
- Previous filing in this sequence was filed on 24 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001981291
Primary reporting owner
JAIN ABHINAV
- Relationship
- Director
- Address
- C/O AYTU BIOPHARMA, INC., 7900 EAST UNION AVENUE, SUITE 920, DENVER
- Signature
- /s/ Ryan J. Selhorn as attorney-in-fact for Abhinav Jain
- Signature date
- 30 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AYTU
transaction
Common Stock
Award
- Transaction value
- Shares
- +10,000
- Change %
- +51%
- Price
- $0.000000*
- Shares after
- 29,500
- Date
- 28 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Grant of restricted stock, which vest on July 28, 2027.